Healthcare Equipment and Supplies
Company Overview of Accellent, Inc.
Accellent, Inc. develops and manufactures minimally invasive devices and delivery systems for cardiovascular, stimulation therapy, neurovascular, and peripheral vascular applications. Its cardiology products include interventional vascular, cardiac rhythm management, pacemakers, ICDs and CRT implantable pulse generators, electrophysiology ablation catheter devices, and cardiac surgery/structural heart disease solutions. The company also provides drug delivery solutions, such as auto injection systems, cannula based delivery systems, implantable seeds, tubes, catheters, delivery systems, infusion and IV connector systems, and patient wearable or constant variable delivery systems. In addition...
100 Fordham Road
Wilmington, MA 01887
Founded in 2000
Key Executives for Accellent, Inc.
Chairman and Chief Executive Officer
Owner and Chief Operating Officer
Owner and Chief Administrative Officer
Chief Financial Officer and Senior Vice President
Executive Vice President, President of Cardio & Vascular Business and Chief Operating Officer of Cardio & Vascular Business
Compensation as of Fiscal Year 2015.
Accellent, Inc. Key Developments
Accellent Inc to Close Arvada, Co Site; Consolidates Galway, Ireland Operations
Sep 10 14
Accellent Inc. announced the decision to close its Arvada, CO site and to consolidate its two Galway, Ireland sites into one. A decision was also made to consolidate the company's two Galway, Ireland sites into one location. The two sites are located less than three miles away from one another. It is expected that the majority of employees will remain with the company once the consolidation is completed. Once the closure and combinations are completed, Accellent (Lake Region Medical) will continue to operate 15 sites throughout the world. The company has positioned each site as a center of excellence with focused roles and responsibilities within its product category and scope of capabilities.
Joe Fleischhacker Joins Accellent, Inc. as Board of Director
Mar 12 14
Accellent Inc. announced it has completed the acquisition of Lake Region Medical. The Fleischhacker family are significant shareholders in the newly combined company and Joe Fleischhacker is joining the company's Board of Directors and will serve on the senior executive team.
Accellent Inc. Announces Tender Offers for Outstanding Notes
Feb 11 14
Accellent Inc. announced that it has commenced tender offers to purchase for cash: any and all of the $400,000,000 aggregate principal amount of its outstanding 8 3/8% Senior Secured Notes due 2017 and any and all of the $315,000,000 aggregate principal amount of its outstanding 10% Senior Subordinated Notes due 2017 (CUSIP No. 00430X AF4). The Senior Secured Notes Offer and the Senior Subordinated Notes Offer are collectively referred to as the Offers and with respect to each series of Notes, each individually as an ‘Offer’. The early tender date with respect to each Offer is 5:00 p.m., New York City time, on February 25, 2014, and each Offer will expire at 11:59 p.m., New York City time, on March 11, 2014. Tendered Notes may be withdrawn at any time at or before 5:00 p.m., New York City time, on February 25, 2014, but not thereafter, unless the company reduces the consideration for such series of Notes subject to such Offer or is otherwise required by law to permit withdrawals. As described in more detail in the Offer to Purchase of the company dated February 11, 2014 and related Letter of Transmittal, the total consideration for each $1,000 principal amount of Senior Secured Notes validly tendered at or before the Early Tender Date and accepted for purchase by the Company will be $1,044.19 and the total consideration for each $1,000 principal amount of Senior Subordinated Notes validly tendered (and not validly withdrawn) at or before the Early Tender Date and accepted for purchase by the company will be equal to $1,081.00. Such total consideration with respect to each series of Notes is referred to as the ‘Full Tender Offer Consideration.’ The Full Tender Offer Consideration with respect to each series of Notes includes an early tender payment equal to $30.00 per $1,000 principal amount of Notes tendered. Additionally, holders whose Notes are purchased pursuant to the Offers will receive any accrued and unpaid interest up to, but not including, the applicable Settlement Date (as defined below) for the Notes. The Full Tender Offer Consideration with respect to the Senior Subordinated Notes was determined with consideration given to the Company's right to redeem the Senior Subordinated Notes at 107.500% of the principal amount to be redeemed. The Company currently expects to redeem any Senior Secured Notes that remain outstanding after the consummation of the Offers pursuant to the 10% Redemption and, if applicable, the Senior Secured Notes Early Redemption. The company also expects to redeem any Senior Subordinated Notes that remain outstanding after consummation of the Offers pursuant to the Senior Subordinated Notes Early Redemption. The company expects that the redemption prices for Notes that remain outstanding after the consummation of the Offers will be less than the applicable Full Tender Offer Consideration.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|